[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-oa-of-the-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-oa-of-the-knee":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,51,81,108,127,152,174,203,230,256,284,309,348,372,397,425,447,469,490,509,531,549,577,606,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638168","genicular-nerve-block-in-knee-arthroplasty-100638168",false,"NCT07589127","GENicular Nerve Block in KNEE Arthroplasty","GENicular Nerve Block in KNEE Arthroplasty - The GENKNEE Trial","GENKNEE","Inclusion Criteria:\n\n* Symptomatic knee OA grade II-IV according to the Kellgren-Lawrence classification system scheduled for primary total knee arthroplasty\n* American Society of Anesthesiologists (ASA) Physical Status grade I-III\n* Able to provide written informed consent\n* Able to undergo surgery under spinal anesthesia\n\nExclusion Criteria:\n\n* Younger than 18 or older than 80 years\n* ASA physical status IV\n* Allergy to local anesthetics\n* Revision surgery\n* Chronic opioid use (\\> 3 months)\n* Coagulopathy\n* Cognitive impairment\n* Inability to comply with study procedures\n* Patients scheduled for day care surgery.","ALL","18 Years","80 Years",{"count":22,"type":23},70,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn whether a preoperative genicular nerve block (GNB) can reduce pain after knee replacement surgery in adults with knee osteoarthritis (OA) undergoing total knee arthroplasty (TKA). It will also assess whether this treatment can reduce opioid use and improve recovery.\n\nThe main questions it aims to answer are:\n\n* Does a preoperative GNB reduce pain during movement 24 hours after surgery compared with placebo?\n* Does it reduce opioid consumption and improve physical activity and functional outcomes after surgery?\n\nResearchers will compare patients receiving a GNB to patients receiving a placebo injection to see if the nerve block improves postoperative pain and recovery.\n\nParticipants will:\n\n* Be randomly assigned to receive either a GNB or a placebo injection before surgery\n* Undergo standard knee replacement surgery and postoperative care\n* Report pain levels at regular intervals after surgery\n* Complete questionnaires on function, quality of life, and recovery\n* Wear an activity monitor to measure physical activity after surgery\n* Attend follow-up assessments at 1 week, 1 month, and 3 months",[29,30,31],"Osteoarthritis (OA) of the Knee","Total Knee Arthroplasty","Genicular Nerve Block",[33,34,35,36,37],"Osteoarthritis","Knee","Knee osteoarthritis","Total knee arthroplasty","Genicular nerve block","RECRUITING","2026-08-20",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":42},"2026-07-17",{"date":46,"type":23},"2029-06-01",{"name":48,"class":49},"Helse Møre og Romsdal HF","OTHER_GOV",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":50},"100652274","early-phase-1-total-osteo-cartilage-replacement-for-the-treatment-of-osteoarthritis-of-knee-100652274","NCT07769632","Total Osteo-Cartilage Replacement for the Treatment of Osteoarthritis of Knee","Inclusion Criteria:\n\n* Being between 45 and 70 years of age of either gender. (OAK is common in this Age group)\n* Diagnosed with OAK with Kellgren and Lawrence Grading III and IV.\n* No ligamentous laxity and varus or valgus deformity. (In standard TKR patients with ligamentous laxity Constrained Condylar Knee (CCK) with intramedullary stem is used).\n* Patients who wish to have an active lifestyle.\n* Agreeing to participate and signing informed consent voluntarily.\n\nExclusion Criteria:\n\n* Previous knee surgery within six months.\n* Uncontrolled Diabetes Mellitus\n* Chronic Kidney Disease. (Patients on hemodialysis)\n* Metabolic bone disease. (Severe osteoporosis with T Score of -\\\u003C3.5)\n* Patients who will not consent to follow-up.\n* Mental disorders and drug dependency (Patients who cannot understand the consent or the procedure of the TOCR).","45 Years","70 Years",{"count":60,"type":23},10,[62],"EARLY_PHASE1","Young patients who require total knee arthroplasty with metallic and plastic implants will undergo femoral condyle cartilage and top of the tibia with meniscus replacement. With the proposed surgery patients will have increased range of movements so that they can sit on the ground to fulfill their social was of life, which is not possible with the standard of care total knee replacement.",[29],[33,66,67,68,69],"Kellgran and Lawrence","Knee joint","Total knee Replacement","Allogenic graft","NOT_YET_RECRUITING","2026-08-18",{"date":73,"type":42},"2026-08-19",{"date":75,"type":23},"2026-11-01",{"date":77,"type":23},"2027-10-31",{"name":79,"class":80},"AlSalam Hospital","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":50},"100562476","phase-4-systemic-oral-glucocorticoids-for-the-treatment-of-acute-osteoarthritis-pain-in-the-emergency-department-100562476","NCT06603662","Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute monoarticular arthritic joint pain affecting native knee, hip, or shoulder presumed to be related to osteoarthritis\n* Acute pain above baseline starting less than 72 hour prior to ED visit\n* Planned discharge from the ED\n* History of osteoarthritis of the affected joint based on radiography performed at index visit or prior available imaging\n\nExclusion Criteria:\n\n* Trauma to the affected joint within 30 days\n* Injection of affected joint within 60 days\n* Prior arthroplasty of the affected joint\n* History of coronary artery disease, severe gastrointestinal bleeding, gastric\u002Fpeptic ulcer disease, chronic kidney disease with GFR less than 30, or platelet disorders (including von Willebrand disease, hemophilia, severe thrombocytopenia with platelets less than 50 k\u002FmcL)\n* Joint pain suspected to be related to rheumatoid arthritis, gout, septic arthritis, or other non-osteoarthritis autoimmune\u002Finflammatory\u002Finfectious arthritis\n* Chronic\u002Fbaseline use of glucocorticoids (greater than 5 mg daily prednisone or equivalent within previous 7 days) or NSAIDs (daily use for more than 2 days prior to presentation)\n* Daily prescription opioid use or active opioid use disorder\n* Illicit drug use\n* Known allergy\u002Fintolerance to ibuprofen\u002FNSAIDs, prednisone, dexamethasone, or other medication precluding ability to participate in one or more study arms\n* Other contraindications to ibuprofen\u002FNSAIDs or glucocorticoids\n* Planned hospitalization from the ED\n* Pregnancy\n* Incarceration\n* Inability to provide informed consent\n* Other conditions that would preclude compliance with the study protocol and medication dosing",{"count":88,"type":23},192,[90],"PHASE4","The purpose of this clinical trial is to compare the analgesic effects (relief of pain) of glucocorticoids (steroids) and pain medication versus pain medication alone in adult patients presenting to the emergency department with joint pain due to osteoarthritis. Steroids are drugs that can reduce inflammation and are used commonly for many different medical conditions.\n\nIn brief, the central aims of the study are to:\n\n1. Assess the efficacy of adding oral glucocorticoid medications to the standard pain medications used to treat the pain of osteoarthritis.\n2. Assess the safety and tolerability of oral glucocorticoid medication for the short-term treatment of osteoarthritis pain.\n\nWe hypothesize that: 1) The addition of glucocorticoids to standard pain medications will improve reported pain scores at 3 days following the initiation of treatment compared to standard pain medications alone and 2) The use of glucocorticoids will be well tolerated.\n\nParticipants in the study will be randomized (like flipping a coin) into one of three groups:\n\n1. Study Group 1 (Control) receiving placebo pills (no active ingredient) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n2. Study Group 2 (Intervention A) who will receive prednisone (steroid) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n3. Study Group 3 (Intervention B) who will receive one dose of dexamethasone (steroid) followed by placebo pills (no active ingredient) once a day for 4 days, plus ibuprofen (pain medication) for 5 days.\n\nIn all groups, acetaminophen (a different pain medication) can be taken as needed for pain that is not controlled with ibuprofen.\n\nParticipants will:\n\n* Receive follow up phone calls at 1, 3, 7 and 14 days.\n* Report pain scores related to joint pain.\n* Report the number of pills taken of the various medications used in the study.\n* Report any adverse events incurred during the follow up period.",[33,29,93,94],"Osteoarthritis (OA) of the Shoulder","Osteoarthritis (OA) of the Hip",[96,97,98,99],"osteoarthritis","acute pain","glucocorticosteroids","emergency department","2026-08-17",{"date":73,"type":42},{"date":103,"type":42},"2025-02-24",{"date":105,"type":23},"2027-12",{"name":107,"class":80},"WellSpan Health",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":50},"100652586","phase-4-novel-extended-release-bupivacaine-polymer-for-sustained-pain-relief-following-total-knee-arthroplasty-100652586","NCT07775248","Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty","Inclusion Criteria:\n\n* Adult patients age 18 and older undergoing primary total knee replacement by fellowship trained Orthopedic Surgeons in Henry Ford Health System with planned outpatient same-day discharge.\n\nExclusion Criteria:\n\n* Incomplete data in medical records\n* Non-English speakers\n* Chronic opioid use in the last 3 months\n* Ipsilateral joint surgery in the last year\n* Undergoing bilateral knee arthroplasty\n* Cannot tolerate oral medications\n* Swallowing difficulties\n* Intolerance to acetaminophen, anti-inflammatories, muscle relaxants, gabapentinoids, or opioids\u002Ftramadol\n* History of alcohol abuse\n* Drug abuse\n* Renal impairment\n* Peptic ulcer disease\n* GI bleeding\n* Illicit narcotic usage in the past 6 months\n* Chronic liver disease\n* Chronic pain syndromes",{"count":115,"type":23},150,[90],"Participants are being invited to take part in a research study about pain control after total knee replacement surgery (also called total knee arthroplasty or TKA). The goal of this study is to see if a new long-acting medication, called Zynrelef, can control pain after surgery as well as or better than two other common pain treatments - a nerve block or a standard injection into the knee during surgery.\n\nKnee replacement is done to reduce pain and improve movement in people with severe knee arthritis. While the surgery can be very successful, pain during the first few days after surgery can make recovery harder. Many patients need strong opioid pain medicines, but these medicines can have side effects and may lead to dependence. The investigators want to find ways to control pain that reduce or even remove the need for opioids.\n\nIf participants join this study, they will be randomly placed (like flipping a coin) into one of three groups:\n\nStandard injection (PAI) - a mix of medicines injected into the knee during surgery.\n\nZynrelef - a new long-acting medicine put directly into the knee during surgery, along with a smaller dose of the standard injection.\n\nNerve block (ACB) - medicine given near a nerve in the leg before surgery to block pain.\n\nAll participants will get the same medicines before and after surgery, follow the same physical therapy program, and have the same follow-up visits. Participants will be asked to record their pain scores and the pain medicines they take for several weeks after surgery.\n\nThe risks of joining are small and similar to those of routine care. All three pain control methods are already used in regular knee replacement surgery. Possible side effects may include temporary numbness, weakness, or soreness from the injections, and the usual surgical risks such as infection.\n\nParticipants may benefit from better pain control, less need for opioids, and a smoother recovery. The results from this study may also help future patients have safer and more comfortable knee replacements.\n\nTaking part is voluntary. Participants can leave the study at any time without affecting their medical care.",[29],"2026-08-14",{"date":39,"type":42},{"date":122,"type":42},"2025-02-11",{"date":124,"type":23},"2026-10-20",{"name":126,"class":80},"Henry Ford Health System",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":135,"maxAge":20,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":50},"100597984","early-phase-1-anti-diabetic-drug-exercise-and-healthy-diet-for-knee-osteoarthritis-with-overweightobesity-100597984","NCT07065591","Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight\u002FObesity","Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight\u002FObesity, a Randomized Controlled Trial","ADDED","Inclusion Criteria:\n\n* Men and women age between 40 and 80 years old, with overweight or obesity (body mass index ≥23 kg\u002Fm2) according to Hong Kong Centre for Health Protection definition of overweight and obesity.\n* Knee pain for 6+ months with Visual Analogue Scale (VAS) \\> 40mm\u002F100mm and\n* Meet the American College of Rheumatology criteria for knee OA\n* OA referred for consideration for joint replacement\n\nExclusion Criteria:\n\n* Severe radiographic knee OA (Kellgren-Lawrence grade 4) or severe knee pain (VAS\\>80mm\u002F100 mm) that could not tolerate further conservative management;\n* inflammatory arthritis like rheumatoid arthritis, crystal arthritis, etc.\n* Preexisting diabetes on antidiabetic drug or drug allergy to metformin.\n* Recent knee surgery of the same knee\n* Significant bone loss.\n* Concomitant neuromuscular diseases affecting lower limb function.\n* renal or liver impairment precluding use of metformin.\n* VitaminB12 deficiency","40 Years",{"count":137,"type":23},100,[62],"Obesity is associated with increased pain with knee osteoarthritis and increase progression of knee osteoarthritis while weight loss intervention has been shown to reduce pain and requirement of total knee replacement. In this study, the investigators will assess using diet modification with exercise, and metformin, a common, safe, diabetes mellitus medication that has been in use for 70 years to achieve better weight control to reduce knee pain. This helps the investigators to understand whether the combined treatment can reduce joint pain, reduce body weight and improve symptoms and requirement of total knee replacement.",[29],[142,143,144],"knee osteoarthritis","diet modification","exercise therapy",{"date":71,"type":42},{"date":147,"type":23},"2026-08-30",{"date":149,"type":23},"2028-07-17",{"name":151,"class":80},"The University of Hong Kong",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":50},"100639885","cohort-of-lower-extremity-sports-injuries-and-degenerationyongjiang-cohort-100639885","NCT07592871","Cohort of Lower-Extremity Sports Injuries and Degeneration(Yongjiang Cohort)","Bidirectional Cohort of Lower-Extremity Sports Injuries and Degeneration (Yongjiang Cohort)","Inclusion Criteria:\n\n* Patients who plan to receive relevant clinical evaluation or treatment at Ningbo No. 2 Hospital and are able to complete baseline assessment.\n* Patients with a clinical diagnosis of knee-related injury or degenerative knee disease.\n* Patients who are willing to provide informed consent and participate in follow-up.\n\nExclusion Criteria:\n\n* Patients who are unable to complete the core baseline assessments or have substantial missing key clinical information.\n* Patients with severe comorbid conditions or cognitive impairment that may affect assessment of the main outcomes or prevent participation in follow-up.\n* Patients who are considered by the investigator to be unsuitable for inclusion in this cohort.","90 Years",{"count":161,"type":23},500,"2 Years","OBSERVATIONAL","This is an observational cohort study conducted at Ningbo No. 2 Hospital. The study will include patients with knee-related sports injuries or degenerative knee conditions who receive routine clinical care. The purpose is to build a standardized real-world clinical cohort and evaluate knee injury, degeneration, recovery, and long-term outcomes.\n\nAfter informed consent, participants will undergo baseline data collection, including medical history, laboratory tests, questionnaires, X-ray and MRI imaging, and functional assessments. Patients younger than 50 years will mainly be assessed for sports injury and functional recovery, while patients aged 50 years or older will receive additional sarcopenia-related assessments such as grip strength, DXA testing, and gait evaluation.\n\nNo experimental treatment, randomization, or intervention will be assigned. Participants will be followed at about 6, 12, and 24 months after treatment or surgery to assess knee function, imaging changes, reinjury, reoperation, pain, quality of life, falls, and functional decline. The study plans to enroll about 500 participants.",[29],"2026-08-13",{"date":100,"type":42},{"date":169,"type":42},"2026-06-01",{"date":171,"type":23},"2028-05-31",{"name":173,"class":80},"Ningbo No.2 Hospital",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":50},"100633115","imageless-navigation-versus-image-based-navigation-in-robotic-assisted-total-knee-arthroplasty-for-knee-osteoarthritis-100633115","NCT07522489","Imageless Navigation Versus Image-Based Navigation in Robotic-Assisted Total Knee Arthroplasty for Knee Osteoarthritis","Outcomes of Robotic-Assisted Total Knee Arthroplasty With Imageless Navigation Versus Image-Based Navigation: A Randomised, Single-Blinded, Non-Inferiority Trial","Inclusion Criteria:\n\n1. Symptomatic, radiologically confirmed advanced osteoarthritis of the knee.\n2. Patients referred for primary robotic-assisted total knee arthroplasty.\n3. Patients in whom a correctly performed radiograph with designated sensors has confirmed the possibility of performing robotic-assisted total knee arthroplasty with image-based navigation.\n4. Patients capable of giving informed consent to participate in the study and willing to attend all follow-up visits.\n\nExclusion Criteria:\n\n1. No informed consent for the surgery.\n2. No informed consent for taking part in the study.\n3. Pregnancy.\n4. Active infections.\n5. Diagnosed comorbidities: autoimmune arthritis, malignant tumors, serious neurological disorders affecting a reliable functional outcome measurement (e.g., severe stroke, severe Parkinson's disease).",{"count":182,"type":23},146,[26],"The goal of this clinical trial is to learn if imageless navigation is not inferior to image-based navigation in robotic-assisted total knee arthroplasty (RA-TKA) for treating patients with knee osteoarthritis.\n\nThe main questions the study aims to answer are:\n\n1. Does imageless procedure provide functional results comparable to those of image-based navigation?\n2. Are there differences in postoperative complications patients may experience after RA-TKA with imageless and image-based navigation? Researchers will compare imageless navigation with image-based navigation used in total knee arthroplasty to assess whether imageless navigation is comparable for the treatment of knee osteoarthritis.\n\nParticipants will:\n\n1. Answer survey questions about knee pain and function before RA-TKA.\n2. Undergo RA-TKA with imageless navigation or image-based navigation.\n3. Visit the Clinic after 6 months and 12 months after surgery for checkups and to answer the same survey questions about postoperative knee pain and function.",[29,186,187,188],"Knee Pain Arthritis","Total Knee Arthroplasty (TKA)","Robotic Assisted Arthroplasty",[190,191,192,193,194],"Knee Osteoarthritis","Robotic-Assisted Total Knee Arthroplasty","Patient Reported Outcome Measures","Imageless Navigation","Image-based Navigation","2026-08-11",{"date":166,"type":42},{"date":198,"type":42},"2026-08-06",{"date":200,"type":23},"2029-01",{"name":202,"class":80},"Medical University of Warsaw",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":20,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":229},"100584094","phase-2-a-study-to-assess-safety-and-tolerability-of-pcrx-201-in-subjects-with-painful-osteoarthritis-of-the-knee-100584094","NCT06884865","A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee","A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee","Inclusion Criteria:\n\n* Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions.\n* Subjects must be male or female and 45 to 80 years old, inclusive, at Screening.\n* Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable).\n* Subjects must have index knee pain for \\>15 days over the last month before Screening (subject self-reporting is acceptable).\n* Subjects must have received 2 or more failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, \"structured land-based exercise\" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months.\n* Subjects must have a body mass index (BMI) ≤40 kg\u002Fm2 at Screening.\n* Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline.\n* Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline.\n* Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study\n* Subjects must have active synovitis in the index knee as determined by ultrasound Doppler (Part A only) For Part B, participants must have active synovitis in the index knee as determined by contrast-enhanced MRI.\n* Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:\n\n  1. Knee pain\n  2. At least 1 of the following:\n\n  i. Age \\>50 years ii. Morning stiffness \\\u003C30 minutes iii. Crepitus on knee motion c. Osteophytes\n* Subjects must have K-L Grade 2, 3, or 4 (Part A) or K-L Grade 2 or 3 (Part B) in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment\n* Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI (Part A). For Part B, participants need to show the presence of synovitis ≥5 on the Guermazi synovitis scoring scale using contrast-enhanced MRI to be enrolled.\n\nExclusion Criteria:\n\n* Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout\u002Fpseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.\n* Subjects have any active systemic or local infection, including infection of the index knee\n* Subjects are unable to undergo MRI with contrast MRI\n* Subjects with X-ray or MRI exclusionary events\n* Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening\n* Subjects have used any approved or investigational IA drug\u002Fbiologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)\n* Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years\n* Subjects have used IA steroids ≤3 months before screening\n* For Part B, subjects with any surgery related tot he index knee.\n\nOther protocol-defined criteria apply",{"count":211,"type":23},135,[213],"PHASE2","The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is.\n\nResearchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time.\n\nParticipants will be asked to\n\n* Visit the clinic for pretreatment and drug administration\n* Visit the clinic for checkups and tests:\n\n  1. Screening through Week 52: intially weekly, bi-weekly, later monthly\n  2. Week 53 through Week 260 (Year 5): 8 visits throughout the period",[29],[217,186,218],"gene therapy","Osteoarthritis of the Knee","2026-08-04",{"date":221,"type":42},"2026-08-07",{"date":223,"type":42},"2025-02-26",{"date":225,"type":23},"2032-07",{"name":227,"class":228},"Pacira Pharmaceuticals, Inc","INDUSTRY",40,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":237,"maxAge":20,"enrollmentInfo":238,"targetDuration":4,"studyType":24,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":50},"100649971","comparison-of-postoperative-functional-outcomes-between-subvastus-and-medial-parapatellar-approach-in-total-knee-arthroplasty-100649971","NCT07742696","Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty","Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty: a Prospective Random Controlled Trial","Inclusion Criteria:\n\n* Patients aged 50 to 80 who are diagnosed with end-stage knee osteoarthritis that require unilateral primary total knee arthroplasty;\n* Patients who are determined by clinical and laboratory tests to have no absolute surgical contraindications;\n* Patients with good compliance, willing and able to undergo follow-up observations as required and sign the informed consent form;\n\nExclusion Criteria:\n\n* Patients with a history of surgery on the affected knee joint in the past;\n* Patients with neuromuscular diseases;\n* Patients scheduled for knee joint replacement revision surgery;\n* Patients with active knee joint infection or systemic infection;\n* Patients who receive primary joint replacement due to non-knee osteoarthritis, such as rheumatoid arthritis, tuberculous arthritis, traumatic arthritis, etc;\n* Patients with valgus or varus deformity of the knee joint greater than 15°;\n* Patients with knee flexion deformity greater than 15°;\n* Patients whose heart and lung functions are determined by clinical and laboratory tests to be unable to tolerate surgery;\n* Patients with mental disorders who are unable to cooperate with treatment;\n* Patients who is lactating or pregnant;\n* Patients who are unwilling to participate in this study and did not sign the informed consent form;\n* Patients with poor compliance and inability to cooperate in completing the follow-up observers at critical times;\n* For any reason, the researchers believe that the subject is unlikely to complete this study.","50 Years",{"count":239,"type":23},84,[26],"This study aims to compare the effects of the medial parapatellar approach (MP) and the subvastus approach (SV) on postoperative clinical function in total knee arthroplasty (TKA). A total of 84 patients, who visit the Joint Surgery Department of Peking University Third Hospital and are diagnosed with end-stage knee osteoarthritis and require unilateral, primary total knee arthroplasty, will be recruited. The patients will be randomly assigned to two groups, with 42 patients in each group. TKA will be performed using the MP and SV approaches respectively. Postoperative data such as quadriceps muscle strength, the time of first unassisted straight leg raise (SLR), joint range of motion (ROM), KSS score, WOMAC score, SF-12 score, VAS score, and shear wave elastography (SWE) of the medial thigh muscle will be collected. The patients will be followed up for 2 years postoperatively to compare the short-term and long-term clinical functional outcomes of the two surgical approaches.",[29],[244,245,246],"medial parapatellar approach","subvastus approach","total knee arthroplasty","2026-07-29",{"date":249,"type":42},"2026-08-03",{"date":251,"type":23},"2026-07-15",{"date":253,"type":23},"2029-07-15",{"name":255,"class":80},"Peking University Third Hospital",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":266,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":50},"100578338","phase-1-contralateral-corticosteroid-injection-in-total-knee-arthroplasty-100578338","NCT06809998","COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty","COSTI: COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty - A Triple Blinded, Randomized Controlled Trial Pilot Study","COSTI","Inclusion Criteria:\n\n* Patients 18 years of age and older\n* Primary osteoarthritis diagnosis with indication for primary elective unilateral TKA\n* No previous contralateral knee injections (steroids\u002Fbiologics) within one year of study\n* Not scheduled for bilateral TKA or a subsequent staged contralateral TKA within the next six months\n* No previous or active infection or trauma (osseous\u002Fligamentous\u002Fextensor mechanism) on the contralateral knee\n* Contralateral knee pain \\& symptoms - defined as a VAS of \\>4\u002F10 at initial pre-op visit\n* Contralateral knee OA quantified as: Kellgren and Lawrence grade \\>2-4\n\n  * Assessed by PI (AK) who will not be contributing any patients to the study through examination of blinded knee radiographs (3 views: AP\u002Flateral\u002FSunrise)\n* Patient is able to read and understand English and provide informed consent to participation in the study\n\nExclusion Criteria:\n\n* Other aetiologies of OA that warrants TKA (inflammatory or post traumatic arthritis)\n* Cognitive impairment (dementia, Alzheimer's, uncontrolled delirium) which will prevent patients from completing primary outcome measure or comply with follow-up requirements\n* Previous TKA or ORIF or nailing on either knee\n* Previous or active knee infection or extensor mechanism disruption\n* Previous arthroscopy on either knee\n* Medical contraindication to elective TKA surgery",{"count":265,"type":23},60,[267,213],"PHASE1","Through a triple-blinded randomized control trial, the primary purpose of this pilot study is to assess the efficacy of administering peri-operative contralateral corticosteroid injection in patients undergoing TKA. The secondary outcome was to assess the effect of contralateral corticosteroid injection on pain and functional outcomes of patients undergoing TKA.",[270,271,29,272],"Total Knee Anthroplasty","Osteoarthritis(Primary)","Bilateral Knee Osteoarthritis",[262,30,274],"Corticosteroid Injection","2026-07-28",{"date":277,"type":42},"2026-07-30",{"date":279,"type":42},"2025-01-24",{"date":281,"type":23},"2027-08-30",{"name":283,"class":80},"Unity Health Toronto",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":24,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":50},"100649184","web-based-conversational-assistant-after-total-knee-arthroplasty-100649184","NCT07731815","Web-Based Conversational Assistant After Total Knee Arthroplasty","Evaluation of a Web-Based Conversational Postoperative Assistant on Patient Satisfaction and Exercise Adherence After Total Knee Arthroplasty: Protocol of a Pragmatic Randomized Pilot Study With 6-Week Follow-up","CARE-TKA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Primary, unilateral, elective total knee arthroplasty (TKA).\n* Discharged to home following surgery.\n* Ability to use a smartphone or tablet with internet access (patient or caregiver).\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* Revision or bilateral simultaneous TKA.\n* Major postoperative complication precluding home discharge (e.g., admission to intensive care, unplanned return to theatre, or haemodynamic instability).\n* Severe cognitive impairment precluding informed consent or device use.\n* No access to an internet-enabled device.\n* Inability or refusal to complete follow-up.\n* Participation in another interventional study at enrolment.",{"count":265,"type":23},[26],"Total knee arthroplasty (TKA) is one of the most frequently performed elective orthopaedic procedures. Following hospital discharge, patients must manage pain, wound care and home rehabilitation with limited professional support. This pragmatic randomised pilot trial will evaluate whether a web-based conversational postoperative assistant, used in addition to standard care, improves patient satisfaction and exercise adherence during the first 6 weeks after TKA. Forty to sixty patients undergoing primary elective TKA will be randomised 1:1 to standard care with or without access to the conversational assistant. The primary outcome is overall patient satisfaction at 6 weeks. Secondary outcomes include pain intensity, exercise adherence, unplanned healthcare contacts and postoperative complications.",[29],[30,297,298,299,300],"Conversational assistant","Patient Satisfaction","Artificial Intelligence","Digital Health","2026-07-23",{"date":275,"type":42},{"date":304,"type":23},"2026-10",{"date":306,"type":23},"2027-03",{"name":308,"class":80},"Wojciech Sroga",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":237,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":24,"phases":319,"briefSummary":320,"conditions":321,"keywords":331,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":50},"100646109","evaluation-of-choose-to-move-replacement-ready-ctm-rr-100646109","NCT07696650","Evaluation of Choose to Move Replacement Ready (CTM-RR)","Choose to Move Replacement Ready: Implementation and Effectiveness of a Virtual Health-Promoting Intervention for People Awaiting Total Hip or Knee Replacement Surgery","CTM-RR","Inclusion Criteria:\n\n1. Activity coach hired by the Active Aging Society (activity coaches must speak English to participate in the evaluation);\n2. English-speaking older adults (aged \\>=50 years) who participate in CTM-RR will be invited to participate in the evaluation;\n3. Referral partner (People who work in a healthcare setting who refer patients into the program)\n\nExclusion Criteria:\n\n1. non-English speaking activity coach\n2. non-English speaking referral partner",{"count":318,"type":23},210,[26],"Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \\>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR\u002FTHR) for osteoarthritis (OA). The primary goals of this observational study are to describe how the adapted program, Choose to Move Replacement Ready (CTM-RR), is implemented in BC and determine if the adapted program improves health outcomes in people with hip and\u002For knee osteoarthritis who are on surgical waitlists for TKR\u002FTHR. The investigators will also evaluate whether any health benefits achieved by CTM-RR participants are maintained three months after they finish the program and also during the remaining time that they wait for their TKR\u002FTHR surgery.\n\nThe investigators will work with referral partners from hospitals and orthopaedic clinics in BC to recruit participants into CTM-RR. Participants who enrol in CTM-RR will answer online survey questions about the program and about their physical activity, mobility, pain, function, quality of life, willingness to undergo surgery, overall perception of their joint condition, psychosocial health, self-efficacy, social isolation, loneliness, and sedentary time. CTM-RR activity coaches will also answer online survey questions about the program. CTM-RR participants, activity coaches, and referral partners will also participate in interviews about the program.",[322,94,29,270,323,324,325,326,327,328,329,330],"Osteoarthritis (OA)","Total Hip Arthroplasty (THA)","Mobility Limitation","Physical Activity","Older Adults","Social Isolation or Loneliness","Pain","Implementation Science","Sedentary Behaviors",[33,332,333,334,335,336,337,338,328],"Implementation science","Physical activity","Social isolation","Older adults","Mobility","Joint replacement","Loneliness","2026-07-08",{"date":341,"type":42},"2026-07-10",{"date":343,"type":23},"2026-08",{"date":345,"type":23},"2028-08",{"name":347,"class":80},"University of British Columbia",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":4},"100646557","phase-4-extended-post-operative-oral-txa-in-primary-tha-100646557","NCT07685743","Extended Post-operative Oral TXA in Primary THA","Extended Post-operative Oral TXA vs.Standard Perioperative TXA in Primary TJA: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Undergoing primary total knee arthroplasty (TKA) or total hip arthroplasty (THA) for osteoarthritis\n* Ability to provide written informed consent\n* Willingness to comply with study protocol\n\nExclusion Criteria:\n\n* History of venous thromboembolism (DVT or PE)\n* Active malignancy\n* Allergy or contraindication to tranexamic acid (TXA)\n* Post-operative anticoagulation therapy other than aspirin\n* History of color blindness or retinal disease",{"count":356,"type":23},170,[90],"The goal of this clinical trial is to learn if extended post-operative oral tranexamic acid (TXA) - a medication that reduces bleeding by slowing the breakdown of blood clots - can improve functional recovery following surgery in adults undergoing primary total knee or hip arthroplasty for osteoarthritis. The main question it aims to answer is: Does extended post-operative oral TXA improve functional outcomes at 6 weeks post-operatively compared to standard perioperative TXA alone? Researchers will compare patients receiving extended oral TXA to patients receiving matching placebo capsules on the same schedule to see if the extended TXA regimen reduces blood loss, improves early functional outcomes, and reduces pain without increasing complication rates. Participants will receive standard perioperative oral TXA (1.95 g) prior to surgical incision, along with standard VTE prophylaxis. They will be randomly assigned to receive either oral TXA or matching placebo capsules once daily on post-operative days 1, 2, and 3. Participants will attend follow-up visits at 2, 6, and 12 weeks post-operatively to complete functional outcome questionnaires, pain assessments, and - for knee replacement patients - range of motion measurements.",[94,29],[361,362,363],"Tranexamic acid","Patient Reported Outcomes","Arthroplasty","2026-07-06",{"date":339,"type":42},{"date":367,"type":23},"2026-09-01",{"date":369,"type":23},"2028-09-01",{"name":371,"class":80},"Oregon Health and Science University",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":381,"briefSummary":382,"conditions":383,"keywords":387,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":4},"100626011","phase-4-post-operative-pain-relief-zynrelef-or-periarticular-injections-in-ratka-100626011","NCT07430085","Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study","Inclusion Criteria:\n\nMales or females aged 18-89 years\n\nDiagnosed with knee osteoarthritis requiring surgical intervention\n\nIndicated for unilateral RATKA\n\nExclusion Criteria:\n\nPediatric, pregnant, or incarcerated patients\n\nBMI of more than 45 kg\u002Fm2\n\nProlonged opioid use history of \\>5 mg\u002Fday for \\>1 month\n\nHistory of contralateral TKA \\\u003C2 years prior to the index TKA\n\nType 1 Hypersensitivity to NSAIDs or local anesthetics\n\nDiagnosis of severe renal disease","89 Years",{"count":115,"type":23},[90],"Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.",[384,322,29,385,386],"Periarticular Block","Pain After Surgery","Knee Arthroplasty, Total",[388],"Zynrelef","2026-07-02",{"date":364,"type":42},{"date":392,"type":23},"2026-07-31",{"date":394,"type":23},"2028-02-28",{"name":396,"class":80},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":403,"sex":18,"minAge":135,"maxAge":379,"enrollmentInfo":404,"targetDuration":4,"studyType":24,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":50},"100582581","phase-4-pain-perception-during-intra-articular-knee-joint-injection-what-is-the-effect-of-needle-gauge-and-the-use-of-ethyl-chloride-100582581","NCT06865170","Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?","Inclusion Criteria:\n\n1. age ≥ 40 years\n2. fulfillment of the American College of Rheumatology criteria for knee OA\n3. confirmation of knee-related pain and\u002For functional loss by clinical examination.\n4. Patients with either\n\n   1. bilateral knee OA\u002Finjections, or\n   2. unilateral knee OA\u002Finjections.\n5. Agreed to an intra-articular knee joint injection with steroids\n6. Naive to use of ethyl chloride\n\nExclusion Criteria:\n\n1. Arthroscopy of the index knee(s) within the prior 6 months\n2. Steroid injection of the knee(s) within the prior 3 months\n3. Hyaluronic acid or platelet-rich plasma injection of the knee within the prior 6 months\n4. Patient reported prior injection of any type with ethyl chloride spray\n5. Knee effusion requiring aspiration at the time of the procedure\n6. Cognitively impaired individuals",true,{"count":405,"type":23},88,[90],"This study aims to investigate factors that affect the subjective experience of pain during and after intra-articular knee joint injection of steroids by comparing needle gauge size (22 G vs 25 G needles), as well as the presence or absence of topical ethyl chloride spray. Additionally, this study will investigate the effects of other various factors on patients' pain associated with the injection. Lastly, this study aims to determine the effect of patients' subjective pain from the injection on long-term clinical outcomes.\n\nSpecific aims are as follows:\n\nAim 1): Determine the effect of needle gauge size on patient reported pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 2): Determine the effect of ethyl chloride spray on patient reported pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 3): Determine the effect of sex, age, BMI, thigh size, severity of OA, and fear of needles on patient pain associated with an ultrasound-guided intra-articular knee injection.\n\nAim 4) Determine the effect of patient pain from the procedure on longer term clinical outcomes after an ultrasound-guided intra-articular knee steroid injection.\n\nResearchers will obtain data at various time points, including pre-procedural data, immediately after the procedure, 24-48 hours after, and 6 weeks post-procedure.\n\nParticipants will:\n\nConsent to receiving an intra-articular knee joint injection with steroids if indicated.\n\nScore their \"procedural\" pain immediately following the procedure, score their post-procedural \"soreness\" 24-48 hours after via telephone call, and score their overall knee pain about 6 weeks after the procedure via telephone call.",[29,409],"Fear of Needles",[411,412,413,414,415,416],"pain perception","fear of needles","needle gauge","ethyl chloride","corticosteroid injection","25G versus 22G","2026-06-26",{"date":419,"type":42},"2026-06-29",{"date":343,"type":23},{"date":422,"type":23},"2026-12",{"name":424,"class":80},"University of California, Davis",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":18,"minAge":237,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":50},"100568432","pharmacist-physiotherapist-collaborative-management-for-early-knee-osteoarthritis-100568432","NCT06681142","Pharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis","PACE-OA","Inclusion Criteria:\n\n* regularly experiencing pain, aching, or stiffness in and\u002For around the knee for at least 1 month\n* complete the screening PhIT-OA questionnaire\n\nExclusion Criteria:\n\n* Prior total knee replacement or on the waitlist to have your knee replaced\n* Knee surgery within the previous 4 months\n* History of acute injury to knee within previous 6 months\n* Unable to speak and read English\n* Unwilling or unable to visit a physiotherapist at a community physiotherapy clinic (specifically the dates and times of the partnering physiotherapy clinic)\n* Previous physician-diagnosed inflammatory arthritis (including this list): Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Lupus, Gout\n* Physician diagnosed fibromyalgia\n* A sudden, severely painful, hot, swollen joint at any time in the past\n* History of the following medications: csDMARD or bDMARD or tsDMARD, Immunosuppressive, Allopurinol or febuxostat, Colchicine\n* Received a knee joint injection in the past 3 months or have one scheduled in the next 3 months\n* Has completed the GLA:D Hip and Knee program at all in the past",{"count":433,"type":23},125,[26],"Osteoarthritis (OA) is a slowly progressive chronic condition that is associated with aging and is characterized as joint pain. Individuals with early-stage OA usually do not seek medical attention. If and when they do, patients more often present to a pharmacy for over-the-counter medications.\n\nThe investigators want to leverage community pharmacists' accessibility and scope of practice to best support patients with early knee OA. Given there are no disease-modifying treatments for OA, treatment guidelines center on patient education, self-management, and exercise, with medications playing a supporting role. Self-management is an effective strategy that provides a solid foundation for managing this progressive chronic condition and health care professionals like physiotherapists and pharmacists can help with the development and application of these skills.",[29,437,438],"Physiotherapy","Pharmacy","2026-06-23",{"date":417,"type":42},{"date":442,"type":42},"2025-08-13",{"date":444,"type":23},"2027-09",{"name":446,"class":80},"University of Alberta",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":403,"sex":18,"minAge":19,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":50},"100644751","enhancing-voluntary-motion-in-broad-patient-populations-with-modular-powered-orthoses-renewal-100644751","NCT07673328","Enhancing Voluntary Motion in Broad Patient Populations With Modular Powered Orthoses Renewal","Inclusion Criteria:\n\nInclusion criteria for able-bodied, young participants will be:\n\n* Aged between 18 to 65 years\n* Weigh less than 300 lbs (due to challenges in bracing heavier participants)\n* BMI \\\u003C 40 (due to challenges in bracing heavier participants)\n\nInclusion criteria for knee osteoarthritis participants will be:\n\n* Aged between 30 to 85 years\n* Medical diagnosis of patellofemoral and tibiofemoral osteoarthritis\n* Patient reported pain ≥ 4 out of 10 during activities of daily life (to avoid floor effects)\n* Weigh less than 300 lbs (due to challenges in bracing heavier participants)\n* BMI \\\u003C 40 (due to challenges in bracing heavier participants)\n* Ability to walk 6 minutes without assistance from a person (may use walking aid)\n* Ability to ascend\u002Fdescend ramps and stairs with or without the use of handrails\n\nExclusion Criteria:\n\nExclusion criteria for able-bodied, young adult participants will be:\n\n* Pregnant (self-report)\n* Any significant neuromuscular or musculoskeletal disorder that would interfere with the study\n* Unable to walk for 20 minutes\n* History of any cardiovascular, vestibular, or visual diseases and\u002For impairments that may interfere with the study\n* Cognitive deficits that would impair their ability to give informed consent or impair their ability to follow simple instructions during the experiments. Cognitive deficits will be determined by a Mini-Mental State Examination (MMSE) score of \\\u003C22.\n* Adults with a known allergy to medical grade tape\n\nExclusion criteria for knee osteoarthritis participants will be:\n\n* Pregnant (self-report)\n* Any recent lower-extremity fracture (within 6 months)\n* Significant limitation on knee joint range of motion\n* Significant neurological (e.g., stroke) or cardiovascular disorder that may affect the ability to walk\n* Advised by a physician not to walk or exercise\n* Uncontrolled hypertension or diabetes\n* Use of opioids\n* Cognitive deficits or visual impairment that would impair their ability to give informed consent or impair their ability to follow simple instructions during the experiments. Cognitive deficits will be determined by a Mini-Mental State Examination (MMSE) score of \\\u003C22.\n* Adults with a known allergy to medical grade tape","85 Years",{"count":455,"type":23},65,[26],"The overall goal of this project is to establish a novel design and control paradigm for modular, partial-assist powered orthoses (exoskeletons) to enhance voluntary lower-limb motion and manage pain in broad patient populations. Building upon a previous study period that addressed weakness from advanced age or muscle fatigue, this current period extends the technology to novel powered unloader orthoses designed to manage knee osteoarthritis (OA) pain. The investigators hypothesize that by providing 15-30% of biological joint torque, these motorized devices can reduce muscular contributions to painful loads on the joint's surfaces during activities of daily living (ADLs). The project aims to develop a task-agnostic, neural network-based controller and establish the feasibility of reducing knee pain and muscle effort in individuals with multi-compartment knee osteoarthritis.",[459,460,29],"Lower-limb Orthoses","Osteoarthritic Knee Pain","2026-06-22",{"date":419,"type":42},{"date":464,"type":42},"2025-07-18",{"date":466,"type":23},"2030-03-31",{"name":468,"class":80},"University of Michigan",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":24,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":50},"100641068","percutaneous-neurostimulation-in-knee-osteoarthritis-100641068","NCT07637682","Percutaneous Neurostimulation in Knee Osteoarthritis","Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis","Inclusion Criteria:\n\n1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.\n2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).\n3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.\n\nExclusion Criteria:\n\n1. Patients with OA show improvement in pain after physiotherapy.\n2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.\n3. pregnant patients.\n4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.\n5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.\n6. people who had received an intra-articular knee injection within the last 6 months.\n7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.",{"count":137,"type":23},[26],"Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis",[29,480],"Neuromodulation","2026-06-16",{"date":483,"type":42},"2026-06-18",{"date":485,"type":42},"2026-06-02",{"date":487,"type":23},"2026-11",{"name":489,"class":80},"Tanta University",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":507,"locationsCount":4},"100642327","the-effect-of-physical-activity-on-knee-osteoarthritis-pain-and-gait-100642327","NCT07649863","The Effect of Physical Activity on Knee Osteoarthritis, Pain and Gait","The Effect of Retro Walking on Pain and Gait Biomechanics Using Non-linear Analysis in People With Knee Osteoarthritis","Inclusion Criteria:\n\n* Male and female\n* Any ethnicity\n* Adults over 18 years old\n* Meet the UK guidelines for physical activity supported by NICE (National Institute for Health and Care Excellence) and NHS (able to exercise if it is safe with regular breaks)\n* Otherwise, adults with clinically diagnosed knee osteoarthritis according to NICE criteria or confirmed by a healthcare professional able and willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Any musculoskeletal injury\n* Any conditions known to affects gait (e.g. Parkinson's disease or stroke)\n* Any surgical intervention in the previous 12 months on lower limbs\n* Surgical replacement of hip or knee joints\n* BMI (body mass index) over 35\n* Athletes or take part in significant recreational activity\n* Takes any medication known to affect the gait and ability to walk\n* Received an intra-articular injection in the last 3 months\n* Have been told by medical professionals that they should not take part in any intensity exercise\u002Fphysical activity",{"count":498,"type":23},44,[26],"Knee osteoarthritis, a chronic musculoskeletal disease, is the most prevalent type of osteoarthritis and the leading cause of disability and major healthcare costs worldwide. The pathogenesis of the disease is not fully understood and there are few non-invasive disease-modifying therapies available to patients. Therefore, there is a critical need to enhance therapeutic interventions, which requires improvement of our understanding of knee osteoarthritis pathogenesis.\n\nIncreasing evidence suggests that physical activity and exercise training are cost-effective and widely available interventions for the treatment of knee osteoarthritis, however, consideration of type of physical activity and optimal exercise modality are needed to reduce pain, improve gait, knee joint function, stiffness, and muscle weakness in individuals with knee osteoarthritis.\n\nThe aim of this pilot clinical trial is to compare individuals with knee osteoarthritis who have not exercised with individuals that have performed retro walking exercise chosen from the systematic review and survey we have conducted previously to reduce pain and improve gait.\n\nNon-linear analyses will be performed to determine the effects of exercise intervention on gait biomechanics and stability of movement in these patients. These findings may form a basis for recommendations of exercise\u002Fphysical activity interventions for the benefits of patients with knee osteoarthritis including pain reduction, mobility improvement and gait modification.",[29],"2026-06-11",{"date":481,"type":42},{"date":505,"type":23},"2026-07",{"date":422,"type":23},{"name":508,"class":80},"Anglia Ruskin University",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":237,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":24,"phases":518,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":50},"100617832","early-phase-1-long-term-effects-of-mobithron-advance-on-knee-osteoarthritis-aims-to-investigate-the-effects-of-mobithron-advance-on-oa-progression-100617832","NCT07323745","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression","Long-Term Effects of Mobithron Advance on Knee Osteoarthritis","mobithron adv","Inclusion Criteria:\n\n* Males and female patients above 50 years old at the time of recruitment.\n* OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR).\n* OA Grade: Kellgren Lawrence grade 1-3\n\nExclusion Criteria:\n\n* Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).\n* History of joint surgery.\n* Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months.\n* Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease).\n* Patients planning for knee surgery within the research period.\n* Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid",{"count":239,"type":23},[62],"The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are:\n\n* Does long-term administration of Mobithron Advance can modify the progression of knee osteoarthritis with Kellgren-Lawrence grade 1 to 3 in HUSM patients?\n* Does long term usage of Mobithron Advance has safety profile? Researchers will compare the Mobithron Advance drug to a placebo (a look-alike substance that contains no drug) to see if said drug works to treat OA.\n\nParticipants will:\n\n* Undergo pre-study assessment (baseline assessments) during first visit\n* Take oral Mobithron Advance daily for 1 year\n* Visit the clinic once at 3 months, 6 months and 12 months intervals from the initial visit for follow up assessments",[29],[522],"Mobithron Advance","2026-06-09",{"date":525,"type":42},"2026-06-12",{"date":527,"type":42},"2026-05-03",{"date":77,"type":23},{"name":530,"class":80},"Universiti Sains Malaysia",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":18,"minAge":135,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":163,"phases":4,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":547,"locationsCount":50},"100642796","evaluating-the-effectiveness-of-mobithron-xtra-in-patients-with-primary-knee-osteoarthritis-over-a-3-month-period-100642796","NCT07643662","Evaluating the Effectiveness of Mobithron Xtra in Patients With Primary Knee Osteoarthritis Over a 3-month Period","Observational Study to Evaluate the Effectiveness of Mobithron Xtra in Patients With Primary Knee Osteoarthritis Over a 3-month Period","Inclusion Criteria:\n\n* Adults ≥40 years with primary knee osteoarthritis (OA)\n* Radiographic diagnosis of primary knee OA (Grade 2 or 3 on Kellgren-Lawrence scale)\n* Stable physiotherapy regimen for ≥3 months (if applicable).\n* Baseline VAS score ≥ 5\n* No prior surgical intervention for the affected knee\n\nExclusion Criteria:\n\n* Secondary OA (such as post-traumatic and inflammatory arthritis)\n* Grade IV Primary OA\n* Patients on analgesia (e.g., paracetamol, NSAIDs)\n* Patients on Mobithron (P\u002FAdvance\u002FXtra) or glucosamine products\n* Recent intra-articular injections within 6 months\n* Recent\u002Fplanned knee surgery within 3 months\n* Severe comorbidities or cognitive impairment",{"count":137,"type":23},"Knee osteoarthritis is a common condition that causes knee pain, stiffness, reduced mobility, and difficulty performing daily activities. Many patients seek non-surgical treatment options to help manage their symptoms and improve their quality of life.\n\nThis study aims to evaluate the effectiveness and safety of Mobithron® Xtra, an oral health supplement containing hyaluronic acid, undenatured type II collagen, and Boswellia serrata extract, in adults with primary knee osteoarthritis. Participants will take Mobithron® Xtra once daily for 3 months as part of their routine care.\n\nThe study will observe changes in knee pain, stiffness, physical function, treatment satisfaction, and overall perception of improvement using validated patient-reported outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Treatment Satisfaction Questionnaire for Medication (TSQM), and Patient Global Impression of Change (PGIC).\n\nThis is a prospective, multicentre observational study involving patients receiving treatment in participating general practitioner clinics throughout Malaysia. No experimental procedures will be performed, and participants will continue to receive standard clinical care. Safety will be monitored throughout the study by documenting any adverse events reported by participants.\n\nThe findings from this study may provide valuable real-world evidence regarding the role of Mobithron® Xtra in improving symptoms and quality of life among patients with primary knee osteoarthritis.",[29],[142,542],"mobitron","2026-06-08",{"date":502,"type":42},{"date":505,"type":23},{"date":105,"type":23},{"name":548,"class":80},"University of Malaya",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":135,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":24,"phases":560,"briefSummary":561,"conditions":562,"keywords":564,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":50},"100637221","effect-of-high-intensity-laser-therapy-on-femoral-cartilage-in-knee-osteoarthritis-100637221","NCT07584603","Effect of High-Intensity Laser Therapy on Femoral Cartilage in Knee Osteoarthritis","The Role of High-intensity Laser Therapy on Femoral Cartilage Thickness in Patients With Knee Osteoarthritis","HILT-KOA","Inclusion Criteria:\n\n* Male and female participants aged 40-60 years.\n* Diagnosed with knee osteoarthritis (Kellgren-Lawrence grade II or III).\n* Knee pain for at least 3 months.\n* Visual Analogue Scale (VAS) score ≥ 3.\n* Willing to provide written informed consent and comply with treatment and follow-up schedule.\n\nExclusion Criteria:\n\n* History of knee surgery or traumatic knee injury.\n* Inflammatory arthritis (e.g., gout, psoriatic arthritis).\n* History of cancer or psychiatric illness.\n* Cognitive disorders (e.g., Parkinson's disease, Alzheimer's disease).\n* Severe comorbidities limiting exercise (e.g., severe COPD, heart failure, cerebrovascular event).\n* Hip or ankle joint disability.\n* Intra-articular knee injection within the past 3 months.","60 Years",{"count":559,"type":23},58,[26],"This clinical trial will evaluate the effects of High-Intensity Laser Therapy (HILT) on femoral cartilage thickness and other clinical outcomes in people with knee osteoarthritis. Participants aged 40 to 60 years with grade II or III knee osteoarthritis will be randomly assigned to receive either HILT plus conventional physiotherapy or conventional physiotherapy alone. Both groups will receive 12 treatment sessions on alternate days for 4 weeks. The study will assess changes in cartilage thickness using ultrasound, as well as improvements in pain, knee movement, muscle strength, and daily function. Findings from this research may help improve physiotherapy treatment strategies for patients with knee osteoarthritis.",[29,563],"Osteoarthitis",[565,190,566,567,33],"High Intensity Laser Therapy","Femoral Cartilage Thickness","High Level Laser Therapy","2026-05-07",{"date":570,"type":42},"2026-05-13",{"date":572,"type":23},"2026-07-01",{"date":574,"type":23},"2027-05-10",{"name":576,"class":80},"University of Lahore",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":403,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":594,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":50},"100610737","platelet-rich-plasma-for-musculoskeletal-conditions-100610737","NCT07231471","Platelet Rich Plasma for Musculoskeletal Conditions","PRP for MSK","Inclusion Criteria:\n\n* 18+ years old\n* Musculoskeletal pathology that may benefit from a PRP injection\n* Failed other conservative treatments\n\nExclusion Criteria:\n\n* No active malignancy\n* No active infection in the area of injection\n* No platelet disorder\n* No active systemic infections\n* No patients currently undergoing dialysis",{"count":585,"type":23},10000,[26],"The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction.\n\nThis will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.",[322,29,94,93,589,590,591,592,593],"Osteoarthritis Ankle","Elbow Osteoarthritis","Epicondylitis of the Elbow","Plantar Fasciitis of Both Feet","Tendinopathy",[595,596,33,593],"PRP","Platelet Rich Plasma","2026-05-05",{"date":599,"type":42},"2026-05-06",{"date":601,"type":42},"2025-12-29",{"date":603,"type":23},"2035-01-01",{"name":605,"class":80},"University of Utah",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":613,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":24,"phases":616,"briefSummary":617,"conditions":618,"keywords":623,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":631,"leadSponsor":633,"locationsCount":50},"100625073","ketogenic-diet-to-reduce-osteoarthritis-pain-in-mci-100625073","NCT07417891","Ketogenic Diet to Reduce Osteoarthritis Pain in MCI","KDROP-MCI","Inclusion Criteria:\n\n* English speaking\n* Diagnosis of major joint osteoarthritis\n* Diagnosis of mild cognitive impairment\n\nExclusion Criteria:\n\n* Diabetes that requires insulin\n* Cancer requiring chemo- or radiation therapy in the last 2 years\n* Cardiac event within 1 year\n* Recent history of renal stones\n* Diagnosis of fibromyalgia\n* Already following a ketogenic diet\n* Following a dietary pattern that does not allow for a ketogenic approach\n* Unable to control one's diet","55 Years","75 Years",{"count":60,"type":23},[26],"Osteoarthritis and mild cognitive impairment are common conditions that share underlying biological processes related to metabolism and inflammation. This study will examine whether a well-formulated ketogenic diet influences pain, physical function, and cognitive outcomes in adults with osteoarthritis and mild cognitive impairment. Participants will follow a supervised ketogenic dietary intervention, with assessments conducted before and after the intervention to evaluate changes in symptoms and related biological markers. The goal of this study is to better understand shared mechanisms between joint pain and cognitive health and to explore whether a ketogenic dietary approach may support symptom management in these populations.",[94,29,93,33,619,620,621,622],"Mild Cognitive Impairment","MCI","Mild Cognitive Impairment (MCI)","Dementia",[624,625,96,626],"ketogenic diet","chronic pain","mild cognitive impairment","2026-04-30",{"date":629,"type":42},"2026-05-04",{"date":169,"type":23},{"date":632,"type":23},"2027-06-01",{"name":634,"class":80},"University of Kansas Medical Center",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":643,"enrollmentInfo":644,"targetDuration":4,"studyType":24,"phases":646,"briefSummary":647,"conditions":648,"keywords":652,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":50},"100584741","impact-of-bone-marrow-aspirate-injections-in-knee-arthroscopy-100584741","NCT06893302","Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy","Bone Marrow Aspirate Injections in Knee Arthroscopy: A Randomized, Single-Blind, Controlled Trial","BMA","Inclusion Criteria:\n\n1. Require a primary knee arthroscopy for a meniscal injury or focal chondral defect (knee debridement or meniscectomy)\n2. Have Kellgren-Lawrence grade 0 arthritis\n3. Have Outerbridge cartilage grade 2 or lower\n4. Ages 18-64\n\nExclusion Criteria:\n\n1. Have previously undergone ipsilateral knee surgery\n2. Have Kellegren-Lawrence grade 3 or greater\n3. Have received other OrthoBiologics within 3 mo of surgery\n4. Have ligament deficiencies\n5. Need meniscal repair\n6. Need a concomitant osteotomy or other realignment surgery\n7. Have used DMARDs within the last three months\n8. Have a hx of anemia, bleeding disorders, or inflammatory joint disease (rheumatoid arthritis, infectious arthritis, hemophilic arthropathy, Charcot's knee)\n9. Have a hx of metabolic bone disease (osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone)\n10. Patients who are currently pregnant","64 Years",{"count":645,"type":23},50,[26],"This study will examine whether using bone marrow aspirate (BMA) during knee arthroscopy surgery can improve patient outcomes. The investigators will enroll 50 patients who need knee arthroscopy surgery for meniscus injuries or cartilage damage. Like flipping a coin, patients will be randomly assigned to one of two groups of 25 patients each. One group will receive standard arthroscopic surgery plus an injection of bone marrow aspirate, while the other group will receive standard surgery plus a saline (salt water) injection. During surgery, for patients in the treatment group, approximately 4mL (less than one teaspoon) of bone marrow will be taken from their hip bone using a special needle system. A small amount (1mL) will be sent to the laboratory for testing. Patients will be followed for 12 months after surgery and will complete questionnaires about their pain levels and knee function at several time points: before surgery, 2 weeks, 6 weeks, 3 months, 6 months, and 12 months after surgery. These questionnaires will ask about pain, daily activities, and overall improvement.",[649,650,651,29],"Chondral Lesion of the Knee","Meniscal Injuries","Cartilage Defects of the Knee",[653,654,655,656,96,657,658,659,641],"knee arthroscopy","meniscal injury","knee debridement","meniscectomy","cartilage defect","chondral lesion","bone marrow aspirate","2026-04-23",{"date":662,"type":42},"2026-04-27",{"date":664,"type":23},"2026-06",{"date":666,"type":23},"2029-04",{"name":668,"class":80},"Hospital for Special Surgery, New York"]